When Will Solasia Pharma K.K. (TSE:4597) Become Profitable?

With the business potentially at an important milestone, we thought we'd take a closer look at Solasia Pharma K.K.'s (TSE:4597) future prospects. Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The JP¥11b market-cap company posted a loss in its most recent financial year of JP¥1.1b and a latest trailing-twelve-month loss of JP¥1.2b leading to an even wider gap between loss and breakeven. As path to profitability is the topic on Solasia Pharma K.K's investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts’ expectations for the company.

View our latest analysis for Solasia Pharma K.K

According to some industry analysts covering Solasia Pharma K.K, breakeven is near. They expect the company to post a final loss in 2025, before turning a profit of JP¥91m in 2026. Therefore, the company is expected to breakeven roughly 2 years from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 71% is expected, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

We're not going to go through company-specific developments for Solasia Pharma K.K given that this is a high-level summary, though, bear in mind that typically a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

One thing we’d like to point out is that Solasia Pharma K.K has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which typically has high debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.

Next Steps:

There are key fundamentals of Solasia Pharma K.K which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Solasia Pharma K.K, take a look at Solasia Pharma K.K's company page on Simply Wall St. We've also compiled a list of pertinent factors you should further research:

1. Valuation: What is Solasia Pharma K.K worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Solasia Pharma K.K is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Solasia Pharma K.K’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.